BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan
[Business Wire] – BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial more
View todays social media effects on BIND
View the latest stocks trending across Twitter. Click to view dashboard